Ruta Rao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruta Rao has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Amelia Tower
Allegheny General Hospital
1 shared publication Carlene Porter
1 shared publicationGalina Vugman
1 shared publicationGeorge Thomas Budd
Cleveland Clinic Foundation, Cleveland, USA
1 shared publicationJames N. Ingle
Mayo Clinic, Rochester, USA
1 shared publicationJamile M. Shammo
1 shared publication
Latest Publications
- 5 February 2015
- Published by Springer Nature
- p. 99-108
Anti-HER2/neu Therapy in DCIS
- 6 December 2014
- Published by Springer Nature
- p. 15-34
Current Clinical Role of Genetic Profiling in Breast Cancer
- 6 December 2014
- Published by Springer Nature
- p. 15-34
Current Clinical Role of Genetic Profiling in Breast Cancer
- 26 August 2013
- Published by Springer Nature
- p. 381-420
Systemic Therapy
- 17 March 2012
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 13 (2) , 240-248
Patients With Positive Axillary Lymph Nodes: How to Use Genomic Assays
The treatment of breast cancer is continually evolving. Standard treatment for early stage, node positive breast cancer has included adjuvant chemotherapy. As we learn more about differences in a tumor’s genetic makeup that result in different patterns of recurrence and survival, we are starting to include gene expression in addition to the routine clinical and pathological factors when we make treatment recommendations. For lymph node negative, early stage breast cancer, there are two genomic assays in routine use to predict prognosis and benefit from adjuvant chemotherapy. There is emerging data to support that the same tests may also predict prognosis and chemotherapy benefit, or lack thereof, in lymph node positive tumors. Currently there are no standard of care and this is an area in which more research is being done. Given that the biology of breast tumors is independent of nodal status, there are certainly cases of node positive early stage breast cancer where clinicians can feel comfortable making treatment decisions based on genomic assays. These include women with micrometastases in the lymph nodes or those with one to three positive lymph nodes. Currently, the genomic assays are limited to use in tumors that are estrogen receptor positive. It is still clearly the standard of care to administer chemotherapy to estrogen receptor negative, lymph node positive tumors.
- 17 March 2012
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 13 (2) , 240-248
Patients With Positive Axillary Lymph Nodes: How to Use Genomic Assays
The treatment of breast cancer is continually evolving. Standard treatment for early stage, node positive breast cancer has included adjuvant chemotherapy. As we learn more about differences in a tumor’s genetic makeup that result in different patterns of recurrence and survival, we are starting to include gene expression in addition to the routine clinical and pathological factors when we make treatment recommendations. For lymph node negative, early stage breast cancer, there are two genomic assays in routine use to predict prognosis and benefit from adjuvant chemotherapy. There is emerging data to support that the same tests may also predict prognosis and chemotherapy benefit, or lack thereof, in lymph node positive tumors. Currently there are no standard of care and this is an area in which more research is being done. Given that the biology of breast tumors is independent of nodal status, there are certainly cases of node positive early stage breast cancer where clinicians can feel comfortable making treatment decisions based on genomic assays. These include women with micrometastases in the lymph nodes or those with one to three positive lymph nodes. Currently, the genomic assays are limited to use in tumors that are estrogen receptor positive. It is still clearly the standard of care to administer chemotherapy to estrogen receptor negative, lymph node positive tumors.
- 28 September 2010
- Published by Springer Nature in Medical Oncology
- Vol. 28 (S1) , 39-47
Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group
Fenretinide and tamoxifen have additive antitumor effects preclinically. We performed a randomized, placebo-controlled, double-blind adjuvant trial in breast cancer patients treated for 5 years with tamoxifen, with or without fenretinide. Between October 1995 and October 1999, 426 postmenopausal women with hormone receptor-positive breast cancer were randomized. Patients were monitored for efficacy and toxicity. Four hundred and nineteen patients were evaluable. The study was terminated early due to slow accrual. There were no significant differences between treatment groups in DFS, TTR or survival. More patients stopped treatment early on the fenretinide arm than on placebo (P = 0.02). Grade 3/4 toxicities, including visual problems and musculoskeletal complaints were more common in patients receiving fenretinide (P = 0.007). A Night Blindness Questionnaire was used to monitor nyctalopia, which was slightly, but not significantly, more common on fenretinide. In this underpowered study, no significant difference was observed in efficacy between treatment groups. This trial provides important toxicity information about fenretinide, a retinoid that has been used in the prevention setting, because it is the only placebo-controlled, double-blind randomized study ever performed.
- 28 September 2010
- Published by Springer Nature in Medical Oncology
- Vol. 28 (S1) , 39-47
Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group
Fenretinide and tamoxifen have additive antitumor effects preclinically. We performed a randomized, placebo-controlled, double-blind adjuvant trial in breast cancer patients treated for 5 years with tamoxifen, with or without fenretinide. Between October 1995 and October 1999, 426 postmenopausal women with hormone receptor-positive breast cancer were randomized. Patients were monitored for efficacy and toxicity. Four hundred and nineteen patients were evaluable. The study was terminated early due to slow accrual. There were no significant differences between treatment groups in DFS, TTR or survival. More patients stopped treatment early on the fenretinide arm than on placebo (P = 0.02). Grade 3/4 toxicities, including visual problems and musculoskeletal complaints were more common in patients receiving fenretinide (P = 0.007). A Night Blindness Questionnaire was used to monitor nyctalopia, which was slightly, but not significantly, more common on fenretinide. In this underpowered study, no significant difference was observed in efficacy between treatment groups. This trial provides important toxicity information about fenretinide, a retinoid that has been used in the prevention setting, because it is the only placebo-controlled, double-blind randomized study ever performed.
- 1 November 2003
- Vol. 1 (11) , 658
Lymphomatoid granulomatosis treated with rituximab and chemotherapy.
- 1 November 2003
- Vol. 1 (11) , 658
Lymphomatoid granulomatosis treated with rituximab and chemotherapy.